Aro Biotherapeutics
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $41.5M
Overview
Develops targeted RNAi therapies using its proprietary Centyrin platform to deliver genetic medicines to specific tissues.
Genetics & GenomicsRare DiseaseMusculoskeletal
Technology Platform
A proprietary Centyrin platform, consisting of engineered protein scaffolds, that enables tissue-specific delivery of RNA interference (RNAi) therapeutics to silence disease genes.
Funding History
1Total raised:$41.5M
Venture$41.5M
Opportunities
Potential to unlock RNAi therapeutics for tissues beyond the liver, addressing a vast array of genetically defined diseases currently untreatable with genetic medicines.
Risk Factors
Platform risk: unproven clinical efficacy of the Centyrin-siRNA conjugate approach and potential for immunogenicity or off-target effects.
Competitive Landscape
Competes in the advanced RNAi delivery space, where its Centyrin platform must prove advantages over established technologies like GalNAc-siRNA conjugates.